Citations

Clear

623 citation(s) found for "Torres, V".

MON-011 Presentation, Management and Outcomes of Ectopic ACTH Syndrome: an International Multicenter Retrospective Study
Chacko, Shireen R , Torres, Camila A Villavicencio, Lü, Lin , Bandgar, Tushar, Varlamov, Elena V , Paissan, Andrea, Imamudeen, Nasvin, Tabarin, Antoine, Shah, Rutu, Peersen, Anina, Kaplan, Jennifer B. , Varghese, Jeena , Yamichannaiah, Chethan, Yu, Kai , Waguespack, Steven G. , Belaya, Zhanna E. , Bandgar, Tushar , Sada, Alaa , Ragnarsson, Oskar , Altieri, Barbara , Newman, Andrew J , Vibhatavata, Peeradon , Tóth, Miklós , Badiu, Corin , St‐Jean, Matthieu , Falhammar, Henrik , Haberbosch, Linus , Bobrowicz, Małgorzata , Gadelha, Mônica R. , Young, William F. , Kaplan, Jennifer, Habra, Mouhammed Amir , Golounina, Olga O. , Mel'nichenko, Galina Afanas'evna , Lila, Anurag Ranjan , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1344 Get It

Abstract Disclosure: S.R. Chacko: None. C.A. Villavicencio Torres: None. K. Yu: None. S.G. Waguespack: None. L. Lu: None. Z. Belaya: None. T. Bandgar: None. A. Sada: None. O. Ragnarsson: None. B. Altieri: None. A. Newman: None. P. Vibhatavata: None. M. Tóth: None. E.V. Varlamov: None. C. Badiu: None. A. Paissan: None. M. St-Jean: None. H. Falhammar: None. N. Imamudeen: None. L. Haberbosch: None. M. Bobrowicz: None. A. Tabarin: None. R. Shah: None. M.R. Gadelha: None. A. Peersen: None. W.F. Young: None. J. Kaplan: None. J. Varghese: None. M.A. Habra: None. O. Golounina: None. G.A. Melnichenko: None. A.R. Lila: None. C. Yamichannaiah: None. I. Bancos: None. Context: Cushing syndrome (CS) due to ectopic ACTH secretion (EAS) is a rare condition, associated with severe hypercortisolism and consequent morbidity and mortality. Its varied and often emergent presentation make diagnosis and treatment challenging. Objectives: 1.Characterize clinical and biochemical presentation of EAS. 2.Describe the scope of hypercortisolism-related complications, overall and CS-specific mortality. 3.Identify factors associated with CS-specific mortality. Methods: We conducted a multicenter retrospective cohort study in patients with EAS at 37 centers. Outcomes were clinical/biochemical severity scores, complications, overall and CS-specific mortality. Results: In 1053 patients [median age at diagnosis 52 years (IQR 37-64), 57% women], metastatic disease was present at diagnosis in 585 (56%). The most common sources of EAS were bronchial neuroendocrine neoplasm (NEN) (304, 29%), pancreatic NEN (114, 11%) and small cell lung carcinoma (114, 11%), with the source of EAS being occult in 192 (18%). Clinical and biochemical severity scores were severe in 475 (45%) and 873 patients (92%) respectively. Hypokalemia was present in 819 patients (78%) in the year prior to diagnosis. Of 342 patients (32%) who had IPSS, 301 (88%) suggested an ectopic source, 7 (2%) a pituitary source, and 23 (7%) were non-diagnostic. Of 595 patients who had both functional and cross-sectional imaging, discordant findings were seen in 122 (21%), concordant lesion was seen on both in 326 (55%), and no lesion in 147 (25%). Of those with discordant results, cross-sectional imaging was accurate in 66 (54%) and functional imaging in 56 (46%).Management included medical therapy alone in 237 (23%), surgical excision of the source of EAS in 158 (15%), bilateral adrenalectomy in 77 (7%) and multimodal therapies in 498 patients (47%). Complications within 5 years after diagnosis included hospitalization related to CS or its therapy in 351 (33%), infection in 337 (32%), thromboembolic event in 102 (10%), cardiovascular event in 83 (8%) and cerebrovascular event in 27 (3%). During a median follow-up of 35 months (IQR 20-122) from CS diagnosis, death occurred in 462 patients (44%), with the cause of death related to CS in 149 (14%). CS-specific mortality was higher in metastatic compared with non-metastatic disease (19% vs. 7%, P<0.001). On multivariable analysis of age, sex, clinical and biochemical severity, older age (HR 1.03, 95% CI: 1.02-1.04) and lower clinical severity score (HR 0.97, 95% CI: 0.94-0.99), were associated with higher CS-specific mortality. Conclusion: Our interim analysis, the largest worldwide, found that most patients with EAS had severe hypercortisolism and hypokalemia. Metastatic disease was present in 56%, and the source of EAS was occult in 18%. CS-related death occurred in 14%, emphasizing the need for urgent management. Presentation: Monday, July 14, 2025
SUN-477 Cross-Sectional Comparison Study of Saliva Cortisone and Saliva Cortisol Versus Current Standard-Of-Care Venipuncture-Based Cortisol Measurements
Torres, Camila A Villavicencio, Ahmadian, Sarina , Fell, Vanessa , Moehnke, Kayla , Grebe, Stefan K. , Chai, Yubo , Taylor, Robert L, Maus, Anthony , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.442 Get It

Abstract Disclosure: C.A. Villavicencio Torres: None. S. Ahmadian: None. V.M. Fell: None. K. Moehnke: None. Y. Chai: None. R.L. Taylor: None. S.K. Grebe: None. A.D. Maus: None. I. Bancos: None. Background: Current standard-of-care assessment of adrenal disorders relies on the venipuncture-based total cortisol measurements. Salivary cortisol (SalF) and cortisone (SalE) measurements have advantages such as a more accurate assessment of patients with cortisol-binging globulin abnormalities and the convenience of at-home non-invasive testing. Aims: This study aimed to compare concentrations of cortisol and dexamethasone between clinical (venipuncture-based) and saliva samples. Methodology: We conducted a cross-sectional study (July 2024-January 2025) of adults undergoing overnight dexamethasone suppression test (DST) or cosyntropin stimulation test (CST). Saliva samples were collected alongside clinical samples. Saliva measurements included cortisol, cortisone, and dexamethasone (mass spectrometry), while clinical samples were tested for total cortisol (Roche immunoassay) and, in a subgroup, dexamethasone (mass spectrometry). Results: Of 241 patients (186 (77%) women, median age 53 years (IQR 39-66)), 178 (74%) provided samples as a part of DST and 63 (26%) as a part CST. An inability to provide sufficient saliva for analysis was found in 5 patients (2%). In patients undergoing DST, median post-dexamethasone serum total cortisol was 1.3 mcg/dL (IQR 0.8-2.2), and median serum dexamethasone (SerD) was 0.43 mcg/dL (IQR 0.3-0.6) based on clinical samples, while median SalF was 10.2 ng/dL (IQR 6.6-23.6), SalE was 78.6 ng/dL (IQR 52.8-131.1), and saliva dexamethasone (SalD) was 60 ng/dL (IQR 41-93). SalE (r=0.92, p<.0001) demonstrated a stronger correlation than SalF (r=0.85, p<.0001) when compared with post-dexamethasone serum total cortisol measurements. SalD (r=0.85, p<.0001) correlated with SerD measurements. In patients undergoing CST, median baseline serum total cortisol was 7.2 mcg/dL (IQR 4.6-10) based on clinical samples, while median baseline SalF was 86.6 ng/dL (IQR 38.3-166.3), and median SalE was 707 ng/dL (IQR 347-906). Median peak 60-minute serum total cortisol was 21.5 mcg/dL (IQR 18-24), while SalF was 870.4 ng/dL (IQR 440-2904) and SalE was 2501 ng/dL (IQR 1770-3193). Both baseline (r=0.92, p<.0001) and 60 min peak post-cosyntropin SalE (r=0.84, p<.0001) demonstrated a strong correlation with venipuncture-based measurements. SalF had a weaker than SalE correlation at both baseline (r=0.88, p<.0001) and 60 min peak post-cosyntropin (r=0.79, p<.0001). Conclusion: Our study demonstrates that salivary measurements of cortisone, cortisol and dexamethasone strongly correlate with standard-of-care venipuncture concentrations following DST and CST. SalE showed the stronger than SalF correlation with venipuncture-based serum total cortisol concentrations. Presentation: Sunday, July 13, 2025
MON-745 The Impact Of Elinzanetant Treatment On Bone Health And Body Composition In Postmenopausal Women
Kapoor, Ekta, Hurtado, Sandra , Torres, Maria Jose, Beau, Jeremy, Gkioni, Ioanna, Genga, Kelly, Lewiecki, Edward Michael , Kapoor, Ekta , Navarro, Victor Manuel , Torres, Maria Jose

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.488 Get It

Abstract Disclosure: E.M. Lewiecki: Amgen Inc, Kyowa Kirin, Ultragenyx, Angitia, Radius Health, Inc, Ascendis. E. Kapoor: Fresenius Kabi USA Inc., Astellas Pharma, Estetra SRL, WellFound Inc., Exeltis. S. Hurtado: None. V.M. Navarro: Bayer, Inc. M. Torres: Bayer, Inc. J. Beau: Bayer, Inc. I. Gkioni: Syneos Health LLC (providing service to Bayer), AstraZeneca. K. Genga: Bayer, Inc.. Background: The neuropeptide substance-P and its receptor neurokinin-1 (SP-NK1R pathway) play a role in bone metabolism and remodelling. Pre-clinical evidence also points to a role of this pathway in energy homeostasis. NK-1R antagonists have been proposed as potential therapies in obesity and musculoskeletal disorders like osteoporosis. Elinzanetant (EZN) is a dual neurokinin-1 and -3 receptor antagonist in late-stage development for vasomotor symptoms (hot flashes) associated with menopause. This post hoc analysis evaluates potential benefits of EZN on the skeleton, body weight, and body composition in postmenopausal women. Methods: Data were gathered from exploratory endpoints of the 52-week (wk), placebo (PL)-controlled, OASIS-3 Phase 3 EZN efficacy and safety trial. Mean percentage (%) change in total bone mass (kg) (measured indirectly by bioelectrical impedance analysis at baseline (BL), wks 4, 8, 12, 18, 24, 36, 52); mean % change in bone mineral density (BMD, measured directly by dual-energy X-ray absorptiometry at BL, wks 24 and 52) in femoral neck, total hip, and lumbar spine; and mean % change in key bone turnover markers osteocalcin (OC) and procollagen 1N-terminal propeptide (P1NP) at BL, wks 4, 8, 12, 18, 24, 36, 52 were evaluated. Weight, body mass index (BMI: weight/height2), waist circumference (WC), fat mass index (FMI; fat mass/height2), lean mass index (LMI; lean mass/height2) and body water were measured to monitor body composition at BL and wks 4, 8, 12, 18, 24, 36, 52. A sub-analysis was performed based on FMI at baseline (FMI ≤9 normal fat mass; >9 excess fat mass). Descriptive statistics were used to evaluate all parameters and trends. Results: From BL to wk 52, increasing trends in bone mass were observed with EZN (mean [SD]: 2.81 [1.02] to 2.95 [1.96]) but not PL (mean [SD]: 2.87 [1.09] to 2.87 [1.13]). In parallel, lower BMD reductions were seen in EZN vs PL at all skeletal sites [EZN vs PL, mean % change from BL: femoral neck (0.00% vs -1.22%), total hip (-0.70% vs -1.37%), and lumbar spine (-0.57% vs -1.22%), with considerable variability in both groups (SD range 3.01 - 4.70)]. Lower levels of circulating OC and P1NP were consistently observed over 52 wks of EZN treatment, suggesting a lower rate of bone resorption with EZN vs PL. Trending reductions in weight, BMI, and WC, along with increases in LMI and body water were observed with EZN vs PL. Trends of higher LMI in patients with excess fat, or lower FMI in patients with normal fat at BL were observed with EZN, suggestive of a positive body re-composition with EZN. Conclusions: These data expand on EZN safety profile and further point to novel potential benefits for the skeleton and body composition of postmenopausal women. Further research is warranted to provide conclusive evidence of the benefits of EZN specifically in post-menopausal women with obesity/overweight status or osteoporosis. Sponsorship: Bayer U.S., Whippany, NJ, USA Presentation: Monday, July 14, 2025
SUN-474 Time-Point Intra-Individual Variability in Salivary Cortisol and Cortisone: A Cross-Sectional Study
Ahmadian, Sarina , Torres, Camila A Villavicencio, Fell, Vanessa , Moehnke, Kayla , Grebe, Stefan K., Chai, Yubo , Taylor, Robert L, Maus, Anthony , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.440 Get It

Abstract Disclosure: S. Ahmadian: None. C.A. Villavicencio Torres: None. V.M. Fell: None. K.L. Moehnke: None. Y. Chai: None. R.L. Taylor: None. S.K. Grebe: None. A.D. Maus: None. I. Bancos: None. Background: Salivary cortisol (SalF), and cortisone (SalE) interpretation can be influenced by intra-individual variability arising from cortisol secretion cyclicity, assay performance, and sampling techniques. No studies to date have examined the impact of sampling on intra-individual variability. Methods: We conducted a single-center cross-sectional study of adults evaluated with total serum cortisol measurements as a part of the overnight dexamethasone suppression test (DST) or cosyntropin stimulation test (CST), November 2024- January 2025. Participants were provided with two cotton swabs (salivettes) and asked to collect two consecutive saliva samples immediately after the venipuncture for total cortisol. Each cotton swab was kept in the mouth for 2-2.5 minutes. Saliva was tested for SalF and SalE by mass spectrometry. Variability was examined based on cortisol tertiles. Results: A total of 78 paired saliva samples were obtained from 60 participants (45 [75%] women; median age 55 years [IQR 39-66]), who were undergoing either DST (42 [70%]) or CST (18 [30%]). A total of 10 (17%) saliva samples did not contain a sufficient sample for analysis during the first or second saliva collection (7 [12%] from DST group, and 3 [5%] from CST group).Among 53 patients undergoing DST, the median serum total cortisol was 1.3 mcg/dL [IQR 0.9-3], the median first SalF was 20 ng/dL [IQR 7-28], the median second SalF was 12 ng/dL [IQR 6-23], and the median variability was 11% [IQR 3-22%]. The median first SalE was 69 ng/dL [IQR 54-185], while the median second SalE was 63 ng/dL [IQR 56-178], with a median variability of 6% [IQR 4-10].In patients undergoing CST, peak median serum total cortisol was 20 mcg/dL [IQR 18-24], median first SalF was 809 ng/dL [IQR 536-1227], and median second SalF was 1063 ng/dL [IQR 667-1503], with the median variability of 14% [IQR 8-22]. The median first SalE was 2507 ng/dL [IQR1697-2966], while the median second SalE was 2485 ng/dL [IQR 1530-2976], with a median variability of 9% [IQR 3-12].When examining intra-individual variability of SalF, the variability was lowest in the middle tertile, corresponding to serum cortisol of 1.8-8.9 mcg/dL, at 9% [IQR 5-16]. Variability was higher in the lowest tertile (14% [IQR 0-52]) and the highest tertile (12% [IQR 6-16]). Overall, the variability of SalE was lower than that of SalF: 7% [IQR 4-13] in the lowest tertile, 5% [IQR 2-9] in the middle tertile, and 10% [IQR 4-12] in the highest tertile. Conclusion: We show that saliva sampling may impact the results, with 17% patients providing insufficient sample for analysis, and variability of 9-14% for SalF and 5-10% for SalE. Same time-point sampling-related variability should be considered in interpretation of SalF and SalE measurements. Presentation: Sunday, July 13, 2025
SUN-473 Clinical Utility of the 8-Mg-Dexamethasone Suppression Test in Assessing Hypercortisolism
Salehi, Mahdi , Torres, Camila A Villavicencio, Fell, Vanessa , Yu, Kai , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.439 Get It

Abstract Disclosure: M. Salehi: None. K. Yu: None. C.A. Villavicencio Torres: None. V. Fell: None. I. Bancos: None. Context: The use of the 1 mg overnight dexamethasone suppression test (1 mg-DST) is considered the standard-of-care test for the assessment of hypercortisolism. Scarce data are available on the utility of 8 mg-DST in distinguishing adrenal from pituitary hypercortisolism. Objective: To determine the value of 8 mg-DST in diagnosing hypercortisolism subtype. Methods: We conducted a single-center retrospective cohort study (2005-2024) of consecutive adults who underwent both the 1 mg-DST and the 8 mg-DST within a 6-month period. Only patients with optimal reference standard confirming the type of hypercortisolism were included. Patients were excluded if they had an abnormal DST and dexamethasone concentration <100 ng/dL or were receiving oral estrogen therapy. Delta cortisol [(post 1 mg-DST cortisol- post 8 mg-DST cortisol) x100/post 1 mg-DST cortisol)] was calculated for each patient. Results: A total of 61 patients (50, 82% women, median age 60 years, interquartile range, IQR 47-67) underwent both 1- and 8 mg-DST at least once, with 8 (13%) patients undergoing the 1 mg-DST and 8 mg-DST twice, and 1 (1.6%) patient undergoing both tests thrice. Adrenal hypercortisolism was diagnosed in 44 (72%) patients and pituitary hypercortisolism in 17 (28%) patients. Median post 1 mg-DST cortisol was 4.6 mcg/dL (IQR 2.8-7.2) in adrenal and 13.7 mcg/dL (IQR 7.3-21.7) in pituitary hypercortisolism. Median post 8 mg-DST cortisol was 3.2 mcg/dL (IQR 2.5-6.3) in adrenal and 3.6 mcg/dL (IQR 2.2-7.5) in pituitary hypercortisolism. Median delta cortisol was higher in pituitary hypercortisolism when compared to adrenal hypercortisolism (69%, IQR 25-83 vs 5 %, IQR -20-16, P<0.001). Delta cortisol demonstrated a good discrimination in distinguishing adrenal from pituitary hypercortisolism with a median area under receiver operator of 82% (95%CI 69-92). A cut-off of 25% provided a specificity of > 85%, while a cut-off of -1% yielded a sensitivity of > 85% in diagnosing adrenal hypercortisolism. Conclusion: In this study, we show that performing 8 mg-DST in addition to 1 mg-DST in selected patients with hypercortisolism and calculating delta cortisol is a valuable in distinguishing hypercortisolism subtype. Presentation: Sunday, July 13, 2025
#2139 Renal uric acid microcrystals drive hyperinflammation, cystogenesis and disease progression in ADPKD
Strubl, Sebastian , Holznecht, Nickolas J., Aceves, Brina A., Schimmel, Meg, Koestner, Stella, Grundmann, Franziska , Mueller, Roman-Ulrich, Antczak, Philipp , Torres, Jacob A. , Schimmel, Meg, Alkarkoukly, Samer , Harris, Peter C. , Mueller, Roman-Ulrich, Weimbs, Thomas

Mayo Clinic

Nephrology Dialysis Transplantation | October 22, 2025 | Volume: 40 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaf116.0167 Get It

Abstract Background and Aims Patients with ADPKD exhibit an increased prevalence of kidney stones with a significant overrepresentation of uric acid (UA) stones which has led to the previous suggestion that UA may be associated with disease progression in ADPKD. However, available results are controversial and the exact mechanism remains unknown. Since we have previously reported that calcium-based microcrystals worsen ADPKD disease progression we hypothesized that renal UA crystallization could affect PKD disease progression and aimed to investigate this in animal models of PKD and the AD(H)PKD registry at the University Hospital Cologne. Method WT and Pkd1+/− rats were supplemented with UA and the uricase inhibitor oxonic acid from 8 to 10 weeks of age to induce moderate hyperuricemia causing renal UA crystal deposition. This was followed by washout from 10 to 18 weeks to analyze crystal clearance. For additional treatment with the ketone beta-hydroxybutyrate (BHB) and alkaline Citrate, adult rats received a solution containing 2.1% BHB and 13.75 mM tripotassium citrate/16.75 mM citric acid in the drinking water from 14 to 18 weeks of age. Human data including eGFR, UA levels in serum, spot urine and 24-hour urine and urine pH were used from the AD(H)PKD study (Clinical Trials ID: NCT02497521) and analyzed using multivariable linear models. Results UA crystal deposition in Pkd1+/− rats led to significantly increased kidney growth, tubule dilation and UA crystal burden compared to UA-treated WT controls. Dilated tubules exhibited strong TLR-4 expression, NLRP3 activation, recruitment of peritubular macrophages and intraluminal neutrophils undergoing NETosis. Strikingly—although untreated heterozygous Pkd1+/− rats fail to develop a polycystic phenotype—UA-treated Pkd1+/− rats developed polycystic kidney disease after 8 weeks washout period with persistent activation of TLR4, NLRP3, pericystic macrophages and intracystic neutrophils. UA-treated WT rats displayed a normalization of renal tubules. Previously, we demonstrated that treatment with BHB and Citrate can ameliorate PKD disease progression. BHB has been reported to inhibit TLR4-NLRP3 signaling and citrate can prevent UA deposition due to urine alkalinization. Therefore, we induced UA crystal deposition in Pkd1+/− followed by 4 weeks of normal diet to allow crystal clearance, followed by treatment with BHB/Citrate in the drinking water. Remarkably, BHB/Citrate potently inhibited the progression to PKD in Pkd1+/− rats by ameliorating cyst growth, TLR4-NLRP3 activation, and macrophage and neutrophil recruitment. Translational analysis of UA stone forming parameters in the AD(H)PKD patient registry showed a correlation of serum and urine UA concentration with eGFR slope. However, significance of this association was lost after adjusting for eGFR, age and sex. In contrast, analysis of the Marshal lithogenic risk score which combines urine UA with urine pH to predict the risk for UA crystal/stone formation showed a significant and independent impact on eGFR slope. Conclusion Our results suggest that UA exposure is a sufficient environmental hit to induce cystogenesis in a heterozygous Pkd1 rat model. A heterozygous Pkd1 gene mutation as observed in ADPKD patients creates a hyperresponsive renal phenotype upon UA crystal formation leading to exaggerated tubule dilation, persistent inflammation, fibrosis and progression to PKD. Treatment with BHB/Citrate significantly reduces TLR4-NLRP3 activation and macrophage/ neutrophil recruitment leading to a significant amelioration of UA-induced cystogenesis. We conclude that UA crystal deposition could accelerate PKD disease progression by NLRP3-mediated and macrophage/neutrophil-based hyperinflammation. BHB/Citrate could not only prevent UA crystallization but ameliorate UA-associated kidney injury and ADPKD disease progression. Finally, the translational analysis in the AD(H)PKD patient registry suggest that, although not showing serum uric acid as independent risk factor, the lithogenic risk- largely driven by the combination of urine uric acid and urine pH- could be a driver of PKD disease progression.
Efficacy and Safety of PolarX for Pulmonary Vein Isolation in Atrial Fibrillation: A Systematic Review and Meta‐Analysis
Erzinger, Gabriel , Streit, Rafael Eduardo , Luiz, Laura , Rajith, Gokul , Torres, Matheus Hariel Colin, Braga, Marcelo Antonio Pinheiro , Deshmukh, Abhishek , Silva, Lívia Teixeira Martins e , Ferreira Félix, Iuri, Silva, Livia Teixeira Martins , Luiz, Laura, Rivera, André , Torres, Matheus Hariel Colin, Félix, Iuri Ferreira , DeSimone, Christopher V.

Mayo Clinic

Pacing and Clinical Electrophysiology | October 17, 2025 | Volume: 48 | Issue: 11 | Pages: 1234-1243

10.1111/pace.70070 | PMID 41105686 Get It

ABSTRACT Background The efficacy and safety of PolarX cryoballoon for pulmonary vein isolation (PVI) among patients with atrial fibrillation (AF) is unclear. Methods PubMed, Embase, Cochrane Central, and ClinicalTrials.gov were systematically searched for studies comparing the PolarX vs. standard cryoballoon (CB‐2/CB‐4). Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (95% CIs) were computed for binary and continuous outcomes, respectively. Results This systematic review and meta‐analysis included 2 randomized controlled trials and 18 observational studies with a total of 7107 patients, of whom 3.188 (44.8%) underwent ablation with PolarX. When compared to standard cryoablation, PolarX had similar incidence of atrial arrhythmias recurrence (OR 1.04; 95% CI 0.82–1.32; p = 0.73), acute PVI success (OR 0.91; 95% CI 0.31–2.68; p = 0.98), and procedural duration (MD 3.41; 95% CI ‐2.89 to 9.71; p = 0.29). However, PolarX was associated with higher persistent phrenic nerve palsy (OR 2.17; 95% CI 1.26–3.74; p = 0.005) and a lower nadir temperature in all veins. Additionally, in a subgroup analysis of randomized trials and propensity score matching studies, similar findings were noted for recurrence of atrial arrhythmias. Conclusion In patients with AF undergoing PVI, PolarX had similar acute PVI success, procedural duration, and recurrence of atrial arrhythmias as compared with standard cryoballoon technology, however, was associated with a lower nadir temperature, and higher rates of persistent nerve palsy.
Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study
Lass, Jonathan H. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Beck, Roy W., Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy N. , Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, Neal, Rosselson, Marie, Nykaza, Jim, Jurkunas, Ula V., Venkateswaran, Nandini, Cheung, Michael K., Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, G, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Hardten, David R., Reeves, Sherman, Dreyer, Allison, Mack, Megan, Hamill, M. Bowes , Nguyen, Jessica, Koo, Ellen, Stanfield, Ryan, Greenwood, Michael, Ernst, L, Messer, Brooke, Risbrudt, Nick, Stofferahn, Seth, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Szczotka-Flynn, Loretta, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Kollman, Craig, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Lê, Jimmy T. , Redford, Maryann , Arafah, Baha M. , Greiner, Mark, Johnson, Paula C, Keeler, D. K., Monnier, Vincent M. , Titus, Michael, Verdier, David, Soper, Mark, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Sengupta, Pratim , Wadleigh, Garth, Greiner, Mark A. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hood, Christopher, Sáles, Christopher S. , Sinkey, Chris, Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Croasdale, Christopher, Brown, Gayle Waldheim, Epstein, Rachel H. , Vaidya, Neal, Jurkunas, Ula V. , Cheung, Michael, Prasad, Elizabeth, Toti, Gwen, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Reeves, Sherman, Dreyer, Allison, Mack, Megan, Nguyen, Jessica, Greenwood, Michael, Messer, Brooke, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Schmidt, Gregory A. , Lass, Jonathan, Lass, Jonathan, Price, Marianne O. , Szczotka-Flynn, Loretta, Richards, Leslie, Bauza, Colleen, Beck, Roy W. , Kollman, Craig, McCarthy, Chris, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Greiner, Mark, Johnson, Paula, Titus, Michael, Verdier, David, Soper, Mark, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dingess, Ryan, Sengupta, Paromita

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1053

10.1001/jamaophthalmol.2025.4261 | PMID 41105099 Get It

Importance The effect of cornea donor diabetes on endothelial cell density (ECD) and morphometry after Descemet membrane endothelial keratoplasty (DMEK) is not known. Objective To determine whether endothelial cell loss (ECL) and morphometric changes 1 year after successful DMEK are related to cornea donor’s diabetes status. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2024 at 28 US clinical sites (46 surgeons) and 13 eye banks. Included in the trial were the eyes of recipients (some of whom received tissue from donors without diabetes and others who received tissue from donors with diabetes) who underwent successful DMEK, primarily for Fuchs endothelial corneal dystrophy, and had at least 1 analyzable postoperative endothelial image. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure to achieve an approximate 2:1 distribution. Main Outcomes and Measures ECD, ECL, coefficient of variation in cell area (CV), and percentage of hexagonal cells (HEX) at 1 year from eye bank and postoperative specular central endothelial images. Results A total 1274 eyes of 982 recipients (mean [SD] age, 70 [8] years; 569 female [57.9%]; 816 [64.1%] with tissue from donors without diabetes and 458 [35.9%] with tissue from donors with diabetes) were included in the study. Preoperatively, mean (SD) central ECD in tissue from donors without diabetes and with diabetes were 2676 (290) cells/mm 2 and 2671 (286) cells/mm 2 , respectively. At 1 year, mean (SD) ECL was 28.3% (16.1%) and 28.0% (17.0%), in the donor groups without and with diabetes, respectively (adjusted mean difference = −0.4%; 95% CI, −2.3% to 1.4%), resulting in a mean (SD) 1-year ECD of 1927 (498) cells/mm 2 and 1920 (496) cells/mm 2 , respectively (adjusted mean difference = 10 cells/mm 2 ; 95% CI, −36 to 56; P = .95). No difference in ECD at 1 year associated with diabetes severity was noted ( P = .97). Mean (SD) CV did not differ at 1 year between the 2 groups of eyes (31.5% [4.1%] vs 31.4% [4.1%]; adjusted mean difference = −0.4%; 95% CI, −0.9% to 0.1%; P = .51), and mean (SD) HEX did not differ at 1 year between the 2 groups of eyes (57.7% [5.8%] vs 57.2% [5.8%]; adjusted mean difference = 0.1%, 95% CI, −0.8% to 0.9%; P = .33). Conclusions and Relevance This randomized clinical trial found that ECL and morphometry 1 year after DMEK were not affected by cornea donor diabetes status. With comparable 1-year graft success with tissue from donors with and without diabetes demonstrated in this trial, these findings support the use of corneas from donors with diabetes for endothelial keratoplasty procedures. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate
Price, Francis W. , Szczotka‐Flynn, Loretta , Bauza, Colleen , Reed, Zachariah W., Arafah, Baha M. , Greiner, Mark A. , Johnson, Paula, Keeler, Devon B., Pramanik, Sudeep, Soper, Mark, Terry, Mark A., Titus, Michael S. , Verdier, David D. , Kollman, Craig, Lass, Jonathan H. , Lass, Jonathan H., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lynn, A. G., Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy, Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James L. , Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, N. N., Nykaza, Jim, Venkateswaran, Nandini, Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, Gwen, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark D., Hardten, David R., Reeves, Sherman W., Dreyer, Allison, Mack, Megan, Hamill, Mark, Nguyen, Jessica , Stanfield, Ryan, Greenwood, Michael , Ernst, Lindsay, Risbrudt, Nick, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Beck, Roy, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann , Lê, Jimmy T. , Redford, Maryann , Arafah, Baha, Greiner, Mark, Keeler, Devon, Monnier, Vincent M. , Titus, Michael, Verdier, David, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad I. , Pramanik, Sudeep , Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Wadleigh, Garth, Price, Marianne O. , Mian, Shahzad I. , Patel, Sanjay V. , Pramanik, Sudeep, Titus, Michael S., Beck, Roy W. , Lass, Jonathan H., Group, Diabetes Endothelial Keratoplasty Study, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hardtke, Elainey, Hood, Christopher, Shapiro, Jeremy, Sáles, Christopher S. , Leavy, Lisa, Gordon, DJ, Fox, Jenni, Coonfield, Kristy, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Crosser, Vicki, Croasdale, Christopher, Brown, Gayle Waldheim, Evans, Que, Epstein, Rachel H. , Nykaza, Jim, Jurkunas, Ula V. , Cheung, Michael, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Mack, Megan, Hamill, M. Bowes, Nguyen, Jessica, Koo, Ellen H. , Stanfield, Ryan, Risbrudt, Nick, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Schmidt, Gregory A. , Elbanhawy, Lindsey, Statz, Brianne, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Richards, Leslie, Spruill, Rashad, Bauza, Colleen, Beck, Roy, McCarthy, Chris, Reed, Zachariah, Arafah, Baha, Greiner, Mark, Titus, Michael, Verdier, David, Velhuisen, Paul Van, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Price, Francis, Terry, Mark, Sell, David, Barton, Glenn, Das, Pravamaya, Dingess, Ryan, Madere, Mark, Sengupta, Partha Pratim , Wadleigh, Garth

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1043

10.1001/jamaophthalmol.2025.4253 | PMID 41105094 Get It

Importance If the success of Descemet membrane endothelial keratoplasty (DMEK) is not affected by whether the donor has diabetes, then the donor pool should expand. Objective To determine whether the 1-year DMEK success rate is affected by the presence of diabetes in the donor. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2025 at 28 clinical sites (46 surgeons), with donor corneas provided by 13 eye banks in the US. Included in the study were individuals undergoing low to moderate risk DMEK (95% for Fuchs endothelial corneal dystrophy). Study data were analyzed from April to September 2025. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure (comparable with randomization) to achieve an approximate 2:1 distribution, respectively. Main Outcomes and Measures Graft success at 1 year Results A total of 1097 individuals (1421 study eyes; median [IQR] age, 71 [66-76] years; 631 female [57.5%]) were included in the study. The 1-year cumulative probability of graft success was 96.3% (95% CI, 95.0%-97.5%) among 912 study eyes (64.2%) receiving tissue from donors without diabetes and 97.1% (95% CI, 95.5%-98.4%) among 509 study eyes (35.8%) receiving tissue from donors with diabetes (difference between groups = 0.7 percentage points; 95% CI, −1.2 to 2.6; P = .63). The 1-year cumulative probability of graft success was 96.5% (95% CI, 93.6%-98.9%) in the mild donor diabetes severity subgroup (n = 173) and 97.3% (95% CI, 95.4%-98.8%) in the moderate to severe donor diabetes severity subgroup (n = 336), using a diabetes severity rating scale based on medical history. The rates of primary donor failure, early failure related to surgical complications, and subsequent failure were as follows: 2.5% (23 of 912), 0.7% (6 of 912), and 0.3% (3 of 912), respectively, in recipients of tissue from a donor without diabetes, and 2.6% (13 of 509), 0.4% (2 of 509), and 0%, respectively, among recipients of tissue from a donor with diabetes. There were no failures due to graft rejection. Conclusions and Relevance The 1-year success rate in eyes undergoing DMEK with successfully prepared tissue was very high regardless of donor diabetes status. These results, supported by the separately reported finding that endothelial cell loss and cornea morphometry after 1 year were not affected by donor diabetes status, provide strong support for having no restrictions on the use of tissue from donors with diabetes for DMEK. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Abstract FR435: Artificial Intelligence-Enhanced Electrocardiography for the Detection and Prediction of Arterial Hypertension: A Systematic Review
Baez, Daniel Banegas, Silva-Jiménez, Sashenka , Torres, Abigail Via y Rada, Narváes, Doménica, Quintana, Lynn, Rios-Garcia, Alondra A. , Baez, Daniel Banegas, Rios-García, Wagner , Torres, Abigail Via y Rada, Quintana, Lynn, Arriola‐Montenegro, Jose , Suarez, Maria Lourdes Gonzalez

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.fr435 Get It

Background: Early detection and prediction of arterial hypertension (HTN) are vital to reduce cardiovascular morbidity and mortality. AI has enhanced ECG diagnostic capabilities, enabling detection of latent cardiovascular abnormalities. Aims: This systematic review evaluates current evidence on AI-enhanced ECG for detection and prediction of HTN in in both clinical and subclinical populations. Methods: A search was conducted on April 28, 2025, in PubMed, Scopus, and Web of Science. Gray literature and study reference lists, plus the first 10 pages of Google Scholar, were screened. The review followed PRISMA 2020 guidelines. Bias risk was assessed using PROBAST (for prediction models) and QUADAS-2 (for diagnostic studies). Two reviewers independently performed study selection and data extraction after pilot training. Results: A total of 26 studies were included: 16 focused on detection and 10 on prediction of HTN using AI-enhanced ECG. Overall, 96% reported successful outcomes, underscoring the strong diagnostic and prognostic potential of this approach. Among detection studies, 94% successfully identified hypertensive individuals, classified blood pressure (BP) levels, or evaluated cardiovascular risk. Most were retrospective in design (75%), with internal validation in 44% and external validation in 19%. Sample sizes ranged from 100 to over 120,000, including healthy and cardiovascular patients. Commonly used algorithms included deep Learning, random forest, and ensemble methods, often using single-lead ECG data, highlighting the feasibility of wearable technologies. QUADAS-2 identified 56% of studies had low risk of bias. All prediction studies achieved accurate estimation of systolic/diastolic BP or predicted future HTN onset. Designs were 40% experimental and 50% retrospective. All studies reported internal validation, and 50% included external validation. AI models such as CNNs, ResNet-LSTM, and U-Net were used across clinical and community-based populations, with follow-up periods of up to 6.8 years. Populations were predominantly normotensive or mixed. PROBAST assessments showed 60% low and 40% moderate risk of bias. Conclusion: AI-enhanced ECG is a promising, non-invasive tool for early detection and prediction of HTN. However, external validation and clinical trials are needed to support integration and generalizability.